Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma
暂无分享,去创建一个
E. Kikuchi | M. Oya | K. Shigeta | R. Mizuno | T. Kosaka | S. Mikami | N. Tanaka | Y. Yasumizu | T. Takeda | K. Matsumoto
[1] E. Batourina,et al. Pparg signaling controls bladder cancer subtype and immune exclusion , 2021, Nature Communications.
[2] Y. Qi,et al. Expression Analysis of Same-Patient Metachronous and Synchronous Upper Tract and Bladder Urothelial Carcinoma , 2021, The Journal of urology.
[3] Christopher C. Griffith,et al. Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma , 2021, PloS one.
[4] E. Kikuchi,et al. The clinicopathological characteristics of muscle‐invasive bladder recurrence in upper tract urothelial carcinoma , 2020, Cancer science.
[5] M. Akhtar,et al. CK20 and CK5/6 Immunohistochemical Staining of Urothelial Neoplasms: A Perspective , 2020, Advances in urology.
[6] T. H. van der Kwast,et al. FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?†. , 2020, European urology.
[7] A. Masson-Lecomte,et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update. , 2020, European urology.
[8] R. Huddart,et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. , 2019, The New England journal of medicine.
[9] M. Rubin,et al. Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling , 2019, Nature Communications.
[10] A. Lopez‐Beltran,et al. Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype , 2019, Virchows Archiv.
[11] B. Taylor,et al. Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma , 2018, Clinical Cancer Research.
[12] M. Babjuk,et al. Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. , 2017, European urology.
[13] Y. Okada,et al. Recent advances in renal cell carcinoma from a pathological point of view , 2016, Pathology international.
[14] T. H. van der Kwast,et al. Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] N. Schultz,et al. Genomic Characterization of Upper Tract Urothelial Carcinoma. , 2015, European urology.
[16] O. Cussenot,et al. A Systematic Review and Meta-analysis of Clinicopathologic Factors Linked to Intravesical Recurrence After Radical Nephroureterectomy to Treat Upper Tract Urothelial Carcinoma. , 2015, European urology.
[17] Arndt Hartmann,et al. Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer , 2014, Virchows Archiv.
[18] Steven J. M. Jones,et al. Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.
[19] Choung-Soo Kim,et al. Muscle-invasive bladder cancer developing after nephroureterectomy for upper urinary tract urothelial carcinoma. , 2013, Urologic oncology.
[20] Y. Okada,et al. The prognostic significance of vasohibin-1 expression in patients with prostate cancer , 2013, British Journal of Cancer.
[21] J. Edwards,et al. Expression and prognostic significance of Src family members in renal clear cell carcinoma , 2012, British Journal of Cancer.
[22] K. Bensalah,et al. The impact of tumor multifocality on outcomes in patients treated with radical nephroureterectomy. , 2012, European urology.
[23] T. H. van der Kwast,et al. The FGFR3 mutation is related to favorable pT1 bladder cancer. , 2009, The Journal of urology.
[24] K. Bensalah,et al. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] T. H. van der Kwast,et al. FGFR3 and P53 Characterize Alternative Genetic Pathways in the Pathogenesis of Urothelial Cell Carcinoma , 2004, Cancer Research.
[26] J. Cheville,et al. Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract , 2001, Oncogene.